Stock PRTA PROTHENA CORPORATION PLC
Add to a list
To use this feature you must be a member
Log inSign up

All News Prothena Corporation plc

Equities

PRTA

IE00B91XRN20

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
19.95 USD -0.45% Intraday chart for Prothena Corporation plc -7.85% -45.10%
May. 28 Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License MT
May. 28 Prothena Announces Bristol Myers Squibb Opt-In for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License
MT
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
BU
Prothena Announces Bristol Myers Squibb Opt-In for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
CI
RBC Cuts Price Target on Prothena to $28 From $35, Keeps Sector Perform, Speculative Risk
MT
Prothena: Q1 Earnings Snapshot
AQ
Prothena : Corporate Overview
PU
Earnings Flash (PRTA) PROTHENA CORPORATION Posts Q1 Revenue $50,000
MT
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
BU
Prothena Corporation plc Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Prothena to Report First Quarter 2024 Financial Results on May 8
BU
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia and Lymphoma
AQ
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
BU
Prothena : Director's Report and Financial Statements for Fiscal Year 2023
PU
Prothena to Participate in Upcoming Healthcare Conferences
BU
Prothena Names David Ford as Chief People Officer
MT
Prothena Appoints David Ford to Newly Created Chief People Officer Position
BU
Prothena Appoints David Ford to Newly Created Chief People Officer
CI
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
BU
Prothena Corporation plc Announces Board Changes
CI
Oppenheimer Cuts Prothena Price Target to $80 From $98, Maintains Outperform Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PRTA Stock
  4. News Prothena Corporation plc